Literature DB >> 18762258

Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate.

F C Popp1, E Eggenhofer, P Renner, P Slowik, S A Lang, H Kaspar, E K Geissler, P Piso, H J Schlitt, M H Dahlke.   

Abstract

The induction of tolerance towards allogeneic solid organ grafts is one of the major goals in transplantation medicine. Mesenchymal stem cells (MSC) inhibit the immune response in vitro, and thus are promising candidate cells to promote acceptance of transplanted organs in vivo. Such novel approaches of tolerance induction are needed since, to date, graft acceptance can only be maintained through life-long treatment with unspecific immunosuppressants that are associated with toxic injury, opportunistic infections and malignancies. We demonstrate that donor-derived MSC induce long-term allograft acceptance in a rat heart transplantation model, when concurrently applied with a short course of low-dose mycophenolate. This tolerogenic effect of MSC is at least partially mediated by the expression of indoleamine 2,3-dioxygenase (IDO), demonstrated by the fact that blocking of IDO with 1-methyl tryptophan (1-MT) abrogates graft acceptance. Moreover we hypothesize that MSC interact with dendritic cells (DC) in vivo, because allogeneic MSC are rejected in the long-term but DC acquire a tolerogenic phenotype after applying MSC. In summary, we demonstrate that MSC constitute a promising tool for induction of non-responsiveness in solid organ transplantation that warrants further investigation in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762258     DOI: 10.1016/j.trim.2008.08.004

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  69 in total

1.  Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells.

Authors:  M J Crop; C C Baan; S S Korevaar; J N M Ijzermans; M Pescatori; A P Stubbs; W F J van Ijcken; M H Dahlke; E Eggenhofer; W Weimar; M J Hoogduijn
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

Review 2.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 3.  Mesenchymal stromal cells in renal transplantation: opportunities and challenges.

Authors:  Federica Casiraghi; Norberto Perico; Monica Cortinovis; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-02-08       Impact factor: 28.314

4.  Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye.

Authors:  Min Joung Lee; Ah Young Ko; Jung Hwa Ko; Hyun Ju Lee; Mee Kum Kim; Won Ryang Wee; Sang In Khwarg; Joo Youn Oh
Journal:  Mol Ther       Date:  2014-08-25       Impact factor: 11.454

5.  Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression.

Authors:  Elke Eggenhofer; Felix C Popp; Michael Mendicino; Paula Silber; Wouter Van't Hof; Philipp Renner; Martin J Hoogduijn; Jef Pinxteren; Nico van Rooijen; Edward K Geissler; Robert Deans; Hans J Schlitt; Marc H Dahlke
Journal:  Stem Cells Transl Med       Date:  2013-07-08       Impact factor: 6.940

6.  First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation.

Authors:  Yorick Soeder; Martin Loss; Christian L Johnson; James A Hutchinson; Jan Haarer; Norbert Ahrens; Robert Offner; Robert J Deans; Gil Van Bokkelen; Edward K Geissler; Hans J Schlitt; Marc H Dahlke
Journal:  Stem Cells Transl Med       Date:  2015-06-03       Impact factor: 6.940

Review 7.  Rationale for the potential use of mesenchymal stromal cells in liver transplantation.

Authors:  Morgan Vandermeulen; Céline Grégoire; Alexandra Briquet; Chantal Lechanteur; Yves Beguin; Olivier Detry
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

8.  MSC-based therapies in solid organ transplantation.

Authors:  V Benseler; N Obermajer; C L Johnson; Y Soeder; M D Dahlke; F C Popp
Journal:  Hepatol Int       Date:  2014-01-04       Impact factor: 6.047

9.  Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations.

Authors:  Michaela Hajkova; Barbora Hermankova; Eliska Javorkova; Pavla Bohacova; Alena Zajicova; Vladimir Holan; Magdalena Krulova
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

10.  Prevention of acute liver allograft rejection by IL-10-engineered mesenchymal stem cells.

Authors:  J Niu; W Yue; Y Song; Y Zhang; X Qi; Z Wang; B Liu; H Shen; X Hu
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.